CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data fu...
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data fu...
* Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified ...
SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026by CStone ...
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung ...
SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an inn...
Rapid Advancement Across Core R&D Pipeline * The global, multicenter Phase I/II clinical trial of...
Key Highlights: * Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patien...
* Following approval by the European Commission (EC), sugemalimab has received a new indication a...
* CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clea...
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innov...
SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an inn...
SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innova...
Financial Performance: Strong Year-over-Year Improvement - Total Revenue: RMB 407.2 million, in...
SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association f...
SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biop...
* Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diff...
SUZHOU, China, March 3, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innov...
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of g...
SUZHOU, China, Feb. 9, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innov...